Cargando…
Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival
BACKGROUND: The effect of first‐line chemotherapy on overall survival (OS) may be significantly influenced by subsequent therapy for patients with extensive disease small cell lung cancer (ED‐SCLC). Therefore, we evaluated the relationship between progression‐free survival (PFS), post‐progression su...
Autores principales: | Masubuchi, Ken, Imai, Hisao, Wasamoto, Satoshi, Tsuda, Takeshi, Minemura, Hiroyuki, Nagai, Yoshiaki, Yamada, Yutaka, Kishikawa, Takayuki, Umeda, Yukihiro, Shiono, Ayako, Takechi, Hiroki, Shiihara, Jun, Kaira, Kyoichi, Kanazawa, Kenya, Taniguchi, Hirokazu, Kaburagi, Takayuki, Kagamu, Hiroshi, Minato, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527159/ https://www.ncbi.nlm.nih.gov/pubmed/36062426 http://dx.doi.org/10.1111/1759-7714.14621 |
Ejemplares similares
-
Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer
por: Wasamoto, Satoshi, et al.
Publicado: (2023) -
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022) -
Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
por: Shiono, Ayako, et al.
Publicado: (2022) -
Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
por: Tsuda, Takeshi, et al.
Publicado: (2023) -
Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021)